Crinetics Corp (CRNX) Cash per Single Share

Corporate emblem and logo of Crinetics Pharmaceuticals (CRNX)

A stable geopolitical backdrop supports the development of Crinetics Pharmaceuticals (CRNX), and a chart of the current cash per share is available in the GURU.Markets system, where the latest parameter is 11.38. Crinetics Pharmaceuticals is implementing ESG standards into test bioethics and laboratory ecology. The biotech's strategy relies on creating oral medications for rare endocrine pathologies, which provides a significant competitive advantage.

Cash Funds per Share: Crinetics Pharmaceuticals, Inc. (CRNX) for 07/04/2022 - 09/12/2026

Analytical breakdowns for Crinetics Pharmaceuticals

- market value and analyst target forecast:
- cash position and cash flow details:
Summary company analysis:CRNX (Crinetics Pharmaceuticals)
Manufactured product of Crinetics Pharmaceuticals, Inc.

This indicator determines the liquid safety cushion per ordinary share, allowing the investor to track capital dilution or hidden asset write-downs. By analyzing the annual trend of cash per share, one can assess the ability of Crinetics Pharmaceuticals (CRNX) to fund the development of unique oral medications for endocrine patients without the urgent need for external capital during a period of active commercial growth.